Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects. Tirzepatide provided superior weight loss when compared with semaglutide ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to ...

Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial ...

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...